Stay updated on Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Sign up to get notified when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.

Latest updates to the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for the TIMIOS study is displayed, including its study overview, participant criteria, locations, design, and outcome measures.SummaryDifference38%

- Check13 days agoChange DetectedThe footer revision label was updated from v3.7.2 to v3.8.0 while the page continued to display a 403 error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears, and the site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer’s site revision indicator changed from v3.7.0 to v3.7.1, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the expected study details with an error page. This indicates the page is currently inaccessible due to permissions or server configuration.SummaryDifference16%

- Check62 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, indicating the current revision of the page. This reflects a metadata update rather than a substantive change to study information.SummaryDifference0.1%

Stay in the know with updates to Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.